Health & Fitness
Health and Fitness
Health and Fitness
Thu, March 29, 2012Wed, March 28, 2012Tue, March 27, 2012Mon, March 26, 2012Sun, March 25, 2012Sat, March 24, 2012Fri, March 23, 2012Thu, March 22, 2012Wed, March 21, 2012Tue, March 20, 2012Mon, March 19, 2012Sun, March 18, 2012Fri, March 16, 2012Thu, March 15, 2012Analytical Reports on Abbott Laboratories and GlaxoSmithKline plc - Drug Manufacturers Facing Headwinds
Published in Health and Fitness on Friday, March 23rd 2012 at 5:20 GMT by Market Wire
March 23, 2012 08:15 ET
Analytical Reports on Abbott Laboratories and GlaxoSmithKline plc - Drug Manufacturers Facing Headwinds
NEW YORK, NY--(Marketwire - Mar 23, 2012) - [ www.SignalWatcher.com ] provides members with proprietary analysis of over 10,000 stocks which is updated every day. Today, members can receive their complimentary stock analysis on Abbott Laboratories (
A slew of patent expirations as well as recent Supreme Court rulings could take their toll on major drug manufacturers. In a case deemed to have broad implications for the industry, the Supreme Court has rejected two medical-test patents. The ruling indicates that patenting medical diagnostic tests may become increasingly difficult and that the currently patent-holder friendly environment may be shifting.
[ www.SignalWatcher.com ] brings investors free classic analysis on Abbott Laboratories, GlaxoSmithKline plc and other companies within the Drug Manufacturers - Major industry. This type of analysis is only a fragment of the information members have available to them. To learn more we encourage investors to sign up at [ http://signalwatcher.com/EmailSignup.php ].
The industry also continues to face a number of patent expirations, which can be potentially crippling for industry players without strong pipelines. Companies such as Abbott Laboratories and GlaxoSmithKline Plc. seem focused on expanding their portfolios and, by extension, their revenues. [ www.SignalWatcher.com ] gives traders a unique insight about Abbott Laboratories and GlaxoSmithKline plc by registering now at [ http://signalwatcher.com/abt/March232012.php ]or [ http://signalwatcher.com/gsk/March232012.php ].
Abbott has recently started two Phase 3 clinical trials concerning an investigational use of HUMIRA® (adalimumab) in hidradenitis suppurativa patients, which if successful would position the company well in an underserved area.
Meanwhile, GlaxoSmithKline has announced its filling of marketing applications for two influenza vaccines, up for approval in both the US and the EU.
About Signal Watch
Signal Watch's #1 goal is to help customers successfully engage the markets. For over 20 years, we have been developing the most powerful trading software available anywhere. But the software is only part of our mission. We also provide education and customer support designed to enable our customers to take control of their financial future.
Read our disclaimer by clicking on the following link [ http://www.signalwatcher.com/disclaimers.php ]
